Index

pathophysiology 4–5

© 2015 John Wiley & Sons, Ltd. Published 2015 by John Wiley & Sons, Ltd.
Companion website: www.wiley.com/go/kipshidze/interventionaltherapies
angiogenesis

critical limb ischemia 514–30
mechanisms 514, 515
soft tissue wound healing 550, 552

angiography

acute GI bleeding 459–60
acute stroke 283–4, 291–2
acute upper extremity ischemia 382
critical leg ischemia 315–16
diabetic foot follow-up 350–1
mesenteric ischemia 451
pulmonary AVMs 412–13, 413
AngioJet catheter system (Possis)
acute coronary syndromes 100–1, 487
acute pulmonary embolism 204, 206
acute upper extremity ischemia 384, 385, 386
transcatheter pacing during 546–7
angioplasty, coronary 21
angiosome concept, diabetic foot 351
angiotensin-converting enzyme inhibitors (ACEI) 142, 174
angiotensin receptor blockers 174, 189
AngioJet System, pulmonary embolus 205, 206
ankle-brachial index (ABI) 314, 314–15, 350
antibiotics 350, 392
anti-coagulants 27–31
acute coronary syndromes 173–4, 485
acute pulmonary embolism 534–5
bleeding complications 66–74
future perspectives 38
heparin-compromised patients 60–4, 61
history of development 27–8, 28
late-presenting STEMI 142
monitoring tests 71
newer 27–31, 78, 79
role in cardiology interventions 77–84
see also direct thrombin inhibitors; factor Xa inhibitors
NSTEMI 88
oral see oral anti-coagulants
radial artery access 111–12
reversal effects 72–4
saphenous vein graft PCI 118
antithrombolic therapy, acute coronary syndromes 172
anti-IIa agents see direct thrombin inhibitors
antiplatelet agents
acute coronary syndromes 173, 174, 485–6
bleeding risks 70
critical leg ischemia 322
dual therapy see double antiplatelet therapy
flow diverters for cerebral aneurysms 303

geneic influences on response 49–57
late-presenting STEMI 142
mechanisms of action 41, 42, 54
monitoring tests 71
newer 41–7
NSTEMI 87–8, 88
response variability 43, 49–50
saphenous vein graft PCI 118
transcatheter aortic valve implantation 218
triple therapy 55
antithrombin (AT)
deficiency 60
variant (AT-N135Q-Pro394) 74

antithrombin agents 27–8, 31–3, 32
unanswered questions 36–7
vs heparin 35–6, 36
antithrombotic agents 27–38, 29
acute coronary syndromes 173–4
bleeding complications 66–74
future perspectives 38
generic versions 35
newer oral 31–5, 35–7
saphenous vein graft PCI 118
anti-Xa agents see factor Xa inhibitors
aorta, ascending
acute dissection 355
calcification 215–16
aortic annulus, measurement 213–15
aortic arch
angiography, acute stroke 291
dissections 355–6
aortic dissection
abdominal 445–6, 446
thoracic 358, 360
classification 359
endovascular therapy 353–6
epidemiology 358, 360
symptomatology 359–60
type A 359, 362
type B 353–5, 359, 362–3, 363
aortic regurgitation, ventricular septal defect 245
aortic root calcification 215, 215–16
aortic stenosis (AS) 209–19, 234
balloon aortic valvotomy 209, 218,
234–6
etiology 234
investigations 210–16
medical management and palliative care 218–19
transcatheter aortic valve implantation 210–18
aortic ulcer, penetrating see penetrating aortic ulcer
aortic valve
angulation 215
calcification 215, 215–16
aortic valve implantation, transcatheter (TAVI) 199, 209–19, 234–5
acute/urgent setting 218
left ventricular pacing during 547
patient selection and screening 210
preprocedure investigations 210–16
procedure 216–17, 217
valve sizing 213–15, 215
vascular access 211, 211–13, 212, 213, 214
aortic valve replacement (AVR), conventional 209, 234
aortic valvotomy, balloon (BAV) 199, 209,
234–6
complications 236
indications 218, 234–5
left ventricular pacing during 547
pathophysiology 235
results 236
technique 235, 235
aortography, acute stroke 291
aortoiliac artery disease
endovascular therapy 321–8, 323, 325
treatment principles 316–17
Aperio Thrombectomy system 294
apixaban 34, 35, 63
development 27–8
monitoring tests 72
pharmacological properties 79
reversal of effects 73–4
APPOSITION trials 491–2
aqueous oxygen (AO) treatment, STEMI 502–7
clinical results 503–5, 504–6, 505
indications 503
technique 505–7
argatroban 31, 32, 32–3
development 27
heparin-compromised patients 62
arrhythmias see cardiac arrhythmias
arterial emboli, acute 377–8, 378–9
arterial injuries, upper extremity
iatrogenic 380, 383
traumatic 376–7, 377
arteriogenesis 514–16, 515
arteriovenous fistulas, congenital 419
arteriovenous malformations (AVMs) 410, 419, 423
catheter-based interventions 422–34, 424–35
complications of treatment 429, 429, 439
indications for treatment 429–1, 421
pulmonary see pulmonary arteriovenous malformations
arteritis, upper extremity 380
ascites, TIPS for refractory 398
Aspirex device, pulmonary embolism 204–5, 205
aspirin
acute coronary syndromes 173, 174, 485
double antiplatelet therapy 41, 42
flow diverters for cerebral aneurysms 303
late-presenting STEMI 142
NSTEMI 87, 88
STEMI 106
transcatheter aortic valve implantation 218
atenolol, late-presenting STEMI 142
atherectomy
below-the-knee (BTK) arterial disease 333–6, 343–5
iliac and femoral arterial disease 327–8
atherosclerosis
acute coronary syndromes 4–5
chronic mesenteric ischemia 446–8
penetrating aortic ulcer (PAU) 361
atherosclerotic plaque, coronary artery see coronary artery plaque
atorvastatin, clopidogrel interaction 44
atrial fibrillation 192
emergent ablation therapy 194
mitral stenosis 232
atrial flutter, emergent ablation therapy 194
atrial septal defect (ASD) occluders, pelvic AVM closure 429, 432
restrictive 253, 262
transcatheter closure 198, 199
atrial septostomies 253–63
balloon technique see balloon atrial septostomy
blade technique 262–3
indications 253–4
static balloon dilation 260, 261
stenoting interatrial septum 255, 256, 257, 260–2
techniques 254–63
transseptal puncture 254–6, 255, 256
atrioventricular (AV) block
after transcatheter VSD closure 244
reperfusion-related 189, 191
distal embolic protection devices
acute coronary syndromes 99–100, 101, 486
late presenting STEMI 141
renal artery stenosis
interventions 368–70
saphenous vein graft PCI 120, 120–1, 121, 122
distal embolization (DE)
coronary interventions 99, 141
critical limb ischemia interventions 328
saphenous vein graft PCI 117, 120, 123
diuretics, reperfusion arrhythmias 190
dopamine, cardiogenic shock 159
Doppler ultrasound, critical leg ischemia 315
double antiplatelet therapy (DAPT) 41, 42, 49
acute coronary syndromes 173
late-presenting STEMI 142
driving, after acute coronary syndromes 177
drug-eluting balloons (DEBs)
acute coronary syndromes 146–50
clinical studies 148–50, 149
procedure 147, 148
critical leg ischemia 317, 328, 339
device features 147
drug-eluting beads, transarterial
chemoembolization (DEB-TACE), liver tumors 404
drug-eluting stents (DES)
acute coronary syndromes 146, 487–90, 490, 491
critical leg ischemia 317, 318, 326–7, 342–3
mesenteric ischemia 451
saphenous vein graft disease 118, 119
unprotected left main coronary artery (ULMCA) 183–4
dual antiplatelet therapy see double antiplatelet therapy
duodenal ulcer, bleeding 462
duplex ultrasonography
acute upper extremity ischemia 380–1
critical leg ischemia 315, 322
diabetic foot follow-up 350
mesenteric vascular disease 453
DX 9065a 34
ECASS studies 290
echocardiography (including transthoracic echocardiography; TTE)
balloon atrial septostomy 257, 258
mitral stenosis 232, 233, 233
prosthetic mitral valve
dysfunction 228–9
pulmonary AVMs 412
transcatheter aortic valve implantation 210
transcatheter pulmonary valve replacement 271, 273
transcatheter VSD closure 247, 249, 250
transesophageal see transesophageal echocardiography
transseptal puncture of interatrial septum 255–6
edoxaban 34, 63, 79
Edwards-SAPIEN transcatheter heart valve (THV) 267, 267–8, 268
aortic valve implantation 209, 213
pulmonary valve replacement 266, 269, 269–70, 270, 272–3, 273
EkoSonic Endovascular System (EKOS) 205, 536
acute pulmonary embolism
acute stroke 296–7
acute upper extremity ischemia 383, 384
diastology, vulnerable plaque 20
elderly patients
cardiogenic shock 155, 155, 158–9
long-term management of acute coronary syndrome 173
postinfarction ventricular septal defect 239
transcatheter treatment of valvular heart disease 199
electrocardiogram (ECG) 210, 223
electrophysiological testing, acute coronary syndromes 176
ELEVATE TIMI-56 trial 55
elevation pallidor/dependent rubor test 314
emboli
acute arterial 377–8, 378–9
acute mesenteric occlusion 442, 443
embolitic materials
acute arterial injury 386, 386
high-flow vascular malformations 424–7, 425–6, 428–9
pulmonary AVMs 414, 414, 415, 416
uterine fibroids 477
embolitic protection devices, distal see distal embolic protection devices
embolization
catheter-based therapeutic see embolotherapy
device, VSD closure 248–9
distal see distal embolization paradoxical 411
embolotherapy (catheter-based embolization)
acute arterial injury 386, 386
acute GI bleeding 459, 461–3, 462–4
AVMs 422–3, 424–35
complications 439–40
portosystemic collaterals, during TIPS 396
pulmonary AVMs 413–15, 414–17, 427
uterine fibroids see uterine fibroid embolization
vascular malformations 422
EMERALD trial 101
EMERAS trial 137
genaprilat, reperfusion arrhythmias 189
endocarditis, transcatheter VSD closure and 248
endoglin (ENG) 411
endothelial dysfunction, biomarkers 9
endothelial progenitor cells (EPCs) 516, 517
administration, critical limb ischemia 523–30, 524–9
endotipsitis 392
EkoSonic Endovascular System
endovascular abdominal aneurysm repair (EVAR), renal artery occlusion after 368
enoxaparin, acute coronary syndromes 88, 106
epifibatide, acute coronary syndromes 87–8
E-selectin 9
esophageal variceal bleeding, TIPS 397–8
ethanol see alcohol
ethylenedinitrovin alcohol copolymer
(Onyx) 425, 426, 426
eValve clip 226, 227
fluorodeoxyglucose imaging, after acute coronary syndromes
acute coronary syndromes 165
pediatric arrhythmia ablative therapy 193
extracorporeal shock wave therapy (ESWT), soft tissue wounds 549–57
basic research 549–53, 551–3
clinical experience 553–7, 554–5, 556
extremities see limbs
factor VIIa, recombinant (rFVIIa) 72, 73–4
factor VIII inhibitor bypassing activity (FEIBA) 74
factor Xa plasma-derived (pd-factor Xa) 74
recombinant 74
factor Xa inhibitors 33–5, 34, 78
bleeding complications 83
heparin-compromised patients 63
pharmacological properties 79
reversal of effects 34, 37, 73–4
role in cardiology interventions 77–84, 81–2
unanswered questions 36–7
vs heparin 35–36, 36
femoral approach
acute stroke interventions 291
balloon atrial septostomy 257, 260
transcatheter aortic valve implantation 211, 212
transcatheter pulmonary valve replacement 268–9
femoropopliteal artery disease
endovascular treatment 321–8
intervention techniques 316, 316–17
femoral popliteal 368
fibrolytic therapy see thrombolytic therapy
fibroblast growth factor (FGF) gene therapy, critical limb ischemia 518, 521
FilterWire EX device 120, 120–1
FINESE study 108
FIRE trial 121
flap surgery, extracorporeal shock wave therapy 550, 551–2
flow diverters (FDs), cerebral aneurysms 302–10
infraluminal 303–9, 305, 308–9
intracranial 310–11
Fluency covered stents 386
Index 563
fondaparinux 33–4, 34, 63
acute coronary syndromes 88
late-presenting STEMI 142
monitoring tests 71
reversal of effects 73, 74
role in cardiology interventions 78
Fontan circulation, failing
postoperative 253, 262
fractional flow reserve (FFR) 118, 368
fresh frozen plasma (FFP) 72
FRISC II trial 89
gastric varices, TIPS 398
gastrointestinal (GI) arterial bleeding,
acute 458–65
angiographic evaluation 459–60
catheter-based interventions 461–3
indications for intervention 458–9
literature review 459
gastrointestinal arteriovenous
malformations (AVMs) 428
gene therapy, critical limb ischemia 516–23,
518–19, 520
genetic testing, neurometabolizers 56–7
GISSI trials 142, 159
glycoprotein (GP) IIb/IIIa inhibitors
acute coronary syndromes 87–8,
88, 486
cardiogenic shock 160
late-presenting STEMI 142
saphenous vein graft PCI 118
gonadotropin-releasing hormone (GnRH)
agonists 474
GRACE (Global Registry of Acute Coronary
Events) 154, 179, 182–3, 238
granulocyte colony-stimulating factor
(G-CSF) 524–30, 527, 529
GRAVITAS trial 44–5, 53–5
growth differentiation factor-15
(GDF-15) 44–5, 53–5
GUSTO trials 154, 155–6, 159
hand ischemia, acute see acute ischemia of
upper extremities
heart block, complete, after transcatheter
VSD closure 244, 250
heart failure
high-output, vascular malformations 421
valvular heart disease 199
hemangiomas 419–20, 420
hemorrhage, recurrent 420–1
hemorrhage see bleeding complications
heparin
acute stroke 295, 296, 297
adverse effects 60, 61
alternative anticoagulants 60–4, 61
history of development 27
low molecular weight see low molecular
weight heparin
newer formulations 29
nonresponders/low responders 60
radial artery access 111–12
unfractionated (UFH) 38
management of bleeding 73
monitoring tests 71
NSTEMI 88
prevention of bleeding 70–1
pulmonary embolism interventions 204
STEMI 106
vs new oral anticoagulants 35–6, 36
heparin-compromised patients 60–4, 61
heparin-induced thrombocytopenia
(HIT) 60, 61
alternative anticoagulants 60–4, 61
direct thrombin inhibitors 31, 32–3, 62
heparin pentasaccharide see fondaparinux
hepatic encephalopathy (HE), complicating
TIPS 400
hepatic hemangiomas 419–20, 420
hepatic malignancies, transarterial
chemoembolization (TACE) 403–8
hepatic vein catheterization 392
hepatic venography, wedged 393
hepatocellular carcinoma (HCC) 403
spontaneous rupture 406
transarterial chemoembolization
(TACE) 403, 404, 406, 407
hepatoocyte growth factor (HGF) gene
therapy, critical limb ischemia
518–19, 521–2
hepatoportal syndrome (HPS), complications
458–9
hepatic veins, see hepatic malformations
(HVMs)
HORIZONS-AMI trial 458–9
Hirschsprung disease 191
HIV, acute retroviral infection 419
hyaluronic acid 156
Hysterectomy, uterine fibroids
271, 272
Hysterectomy with bowel reconstruction
271
Hysterectomy with pelvic lymphadenectomy
271
Hysterectomy with vaginal approach
271
Hysterectomy with vaginal approach and
pelvic lymphadenectomy 271
hypothermia, therapeutic
512
hypertrophic cardiomyopathy 121
hypertrophic obstructive cardiomyopathy
(HOCM), transcoronary alcohol
septal ablation 198–9, 229
hypoplastic left heart syndrome
(HLHS) 253
ablation, transatrial septomxy 256, 257, 258,
259
stenting of interatrial septum 260–1
transseptal puncture of interatrial
septum 254, 255
hypothalamic syndrome 378, 379
hypothymia, therapeutic
acute myocardial infarction 509–12
animal studies 509–10
clinical trials 510–11
conscious patient 511–12
hemodynamic effects 512
acute stroke 297
hypoxia inducible factor-1 (HIF-1), critical
limb ischemia 519, 522–3
hysterectomy, uterine fibroids 474, 480
IABP-SHOCK trials 161, 162, 163
ICAM-1 9
ICE-IT trial 510, 511
idaraparinux 34, 34
iliac interventions, critical limb
ischemia 321–8
Impella left ventricular assist device
acute mitral regurgitation 224, 224
cardiogenic shock 163–5, 164
unprotected left main coronary artery
disease 183
unstable ventricular tachycardia 195
implantable cardioverter defibrillators
(ICD)
acute coronary syndromes 176
emergent ablative therapy for recurrent
shocks 195
IMS (Interventional Management of Stroke)
trials 296–7
infantile hemangiomas 419–20, 420
infections, diabetic foot ulcers 349–50
inferior mesenteric artery (IMA)
disease 447
inferior vena cava (IVC) filters 467–72
complications 471–2, 472
contraindications 469, 470
efficacy 470–1
indications 206, 467–8, 468
suprarenal 468–9, 469
infrapopliteal arterial disease 317–19,
331–6, 338–45
atherectomy 333–6, 342–5
balloon angioplasty 317, 338–9,
340–2
classification 331, 332
cryoplasty 318–19, 339–42
drug-eluting balloons 317, 339
eximer laser-assisted angioplasty 344
stenting 317–18, 343–2
treatment options 316–17, 331–3
INFUSE-AMI study 101, 487
Inoue balloon technique, mitral
valvotomy 233, 235
INSPIRE trial 492
integrated backscatter ultrasound
(IB-US) 20
interatrial septum stenting 107
ablation 26, 261
stenting 255, 256, 257, 260–2
transseptal puncture 254–6, 255, 256
interleukin-10 (IL-10) 10
intermittent claudication (IC) 338
intermittent pneumatic compression (IPC),
critical leg ischemia 319
intracardial artery (ICA)
aneurysms 308, 309
international normalized ratio (INR) 71, 72
International Society on Thrombosis and
Haemostasis (ISTH), definitions of
bleeding 67
intra-aortic balloon counterpulsation
(IABP)
acute mitral regurgitation 224
cardiogenic shock 160–3, 161, 162
postinfarction ventricular septal
defect 239, 239
unprotected left main coronary artery
disease 183
intracardiac echocardiography (ICE),
transcatheter pulmonary valve
replacement 271, 273
intracerebral abscesses 411, 411
intracranial aneurysms see cerebral
aneurysms
intracranial hemorrhage
complicating cardiac interventions 67,
107
complicating stroke therapy 289–90, 295,
297–8, 298
excluding, acute stroke 288
intracranial stenting
acute stroke 294–5
cerebral aneurysms 302
intraluminal recanalization, critical limb
ischemia 325–6
intramural hematoma (IMH), aortic 358, 359, 360–1, 361
symptomatology 359
- treatment 363
intravascular thermography, atherosclerotic plaque 23, 23
intravascular ultrasound (IVUS) coronary plaque 20–1, 21, 22–3
renal artery stenosis 368
ISAR-CABG trial 119
ISAR-SHOCK trial 165
ischemia-modified albumin (IMA) 10–11
ISIS-1 study 142
Jetstream Navitus rotational aspiration system 354, 355
JUMBO-TIMI 26 trial 45
Klippel–Trenaunay syndrome 421, 438, 438
LACI (Laser Atherectomy for Critical Ischemia) trial 333, 344
laser ablation, cardiac arrhythmias 193
laser revascularization see excimer laser revascularization
LATE trial 137
left cardiac sympathetic denervation (LCSD) 196
left main coronary artery disease, unprotected (ULMCA) 179–84
CABG vs PCI 182–3, 184
current guidelines and limitations 179–80, 180
hemodynamic support for PCI 183 outcomes of acute coronary syndromes 180–2
stent choice 183–4
left ventricular assist devices (LVAD) acute mitral regurgitation 224, 224
cardiogenic shock 163, 163–5, 164
emergent ablation of ventricular tachycardia 195–6
unprotected left main coronary artery disease 183
left ventricular pacing, temporary 544–5, 545
clinical studies 545, 546, 547
leg ischemia, critical see critical limb ischemia
Leo intracranial stent 302
leuprolide 474
limbs acute ischemia see acute ischemia of upper extremities
critical ischemia see critical limb ischemia
high-flow vascular malformations 431–4, 433–5
lipid management 172
lipiodol-based transarterial chemoembolization, liver tumors 403–4
liver transplantation, bridge to 405–6
liver tumors, transarterial chemoembolization (TACE) aneurysm 333, 334
lower gastrointestinal bleeding, acute 459, 460
transcatheter arterial embolization 462–3, 464
lower limb ischemia chronic 321
- critical see critical limb ischemia
low molecular weight heparin (LMWH) 29–31
drug interactions 31
generic versions 35
indications 29–30, 30
late-presenting STEMI 142
management of bleeding 73
monitoring tests 71
NSTEMI 88
ultra- 31
Luna device 310, 310–11
lymphatic malformations 438–9, 439
magnetic resonance angiography (MRA) acute upper extremity ischemia 381
critical leg ischemia 315, 316
diabetic foot follow-up 350–1
magnetic resonance imaging (MRI) acute stroke 283–4, 288, 289
aortic valve disease 216
TIPS 392
uterine fibroids 475, 475
vascular malformations 422, 423
Marfan syndrome 358, 360–1
MASTER trial 493
matrix metalloproteinases (MMP) 11, 13
MDRI see ABCB1
median arcuate ligament (MAL) syndrome 448, 448
Mediterranean diet 175, 175
melagatran 32, 33
melanoma, ocular, transarterial chemoembolization (TACE) 405
Melody pulmonic valve (Medtronic) 266–7, 267, 268, 272–3
implantation procedure 269–70, 272
trial inclusion criteria 268, 269
MELT trial 295–6
MERCI clot retriever 292–3, 294
mesenteric arteriovenous malformations (AVMs) 428
mesentric ischemia 442–55
acute (AMI) see acute mesenteric ischemia
chronic (CMI) 442, 446–50, 451–2
complications of interventions 453, 454
endovascular technique and stent selection 451–2, 452
nonocclusive (NOMA) 443, 446
postprocedure follow-up 452–3, 453
single vs multiple vessel intervention 452
mesentric venous thrombosis (MVT) 444–5
metoprolol, cardiogenic shock and 152–3
MGuard stent 492–3, 492–3
microspheres, for embolization 425, 427
microvascular obstruction/ischemia, myocardial after mechanical thrombectomy 100
aqueous oxygen treatment 502, 507
myocardial viability and 139–40
microwave ablation, cardiac arrhythmias 193
middle cerebral artery (MCA) acute occlusion 288–9, 295–6
aneurysm 340–2
Miller atrioseptostomy catheter 257
MitraClip delivery system 225–6
mitral annuloplasty 226
percutaneous methods 227, 227
mitral atresia (MA), atrial septostomy 253, 261
mitral balloon valvotomy (MBV) 199, 221–3, 231–4
complications 234
emergent setting 234
preprocedure evaluation 232–3
results 234
technique 233, 233–4
mitral clip placement 199
acute functional mitral regurgitation 227
ruptured chordae tendineae 225–6, 226
mitral regurgitation (MR), acute 222, 223–9
clinical manifestations 223
complicating balloon valvotomy 234
etiology 223
functional, chronic heart disease with 226–7
hypertrophic obstructive cardiomyopathy 229
investigations 223–4
ischemic 224–5, 225
prosthetic valve dysfunction 227–9, 228
ruptured chordae tendineae 225–6, 226
- treatment 224–9
mitral stenosis (MS) 231–4
balloon mitral valvotomy 199, 221–3, 232–4
congenital, atrial septostomy 253, 261, 261
etiology 231
management 232
pathophysiology 231–2, 232
mitral valve (MV) acute disease 221–9
time-to-edge repair technique 226, 227
orifice area 231
mobile stroke unit (MSU) 282, 288
myeloperoxidase (MPO) 11, 14
myocardial dysfunction, biomarkers 16
myocardial infarction (MI) classification 4
definition 3–4
remodeling after 497
stem cell therapy after 497–501
see also acute myocardial infarction;
non-ST-segment elevation myocardial infarction; ST-segment elevation myocardial infarction
myocardial injury biomarkers 12–16
reperfusion injury 187, 509
myocardial ischemia biomarkers 10–11
chronic, coronary artery occlusion after 139–40
myocardial salvage reperfusion in latecomers 140
time dependency 137–8, 138
myocardial stretch, biomarkers 16
myoglobin 16
myomectomy 474, 480
National Registry of Myocardial Infarction (NRMI) studies 154, 155, 160–1
n-butyl cyanoacrylate (nBCA) 425, 426, 403–8
near-infrared spectroscopy (NIRS), coronary plaque 21
negative pressure wound therapy (NPWT), diabetic foot 349
sinusoidal obstruction syndrome (SOS),
TIPS 399
sirolimus-eluting stents, saphenous vein
graft disease 119
slow flow phenomenon, saphenous vein
graft PCI 117, 121–2
SMASH trial 157, 158–9
SMILE study 142
smoking, tobacco 171–2, 380
SOAP trial 159
sodium tetradeyl sul fate (Sotradecol) 436, 437
Solitaire FR stent 293–4
SOS trial 119
Spectranectic laser device, acute upper
extremity ischemia 385
Speed-Lyse catheter 383–4
spider bite, acute upper extremity
ischemia 382
SpideRx embolic protection device 121
spinal cord stimulation, critical leg
ischemia 319
spironolactone, reperfusion
arrhythmias 190
STABILISE repair, acute aortic
dissection 355
statins 142–3, 172, 218
stem cell therapy, after myocardial
infarction 497–501
cardiogenic shock 500
clinical results 499, 499–500, 500
epicardial intramyocardial
delivery 498–9
intracoronary delivery 498
mechanisms of action 497–8
methodological prerequisites 498
STEMI see ST-segment elevation myocardial
infarction
stenting
acute coronary syndromes 487–93
acute stroke 294–5
acute upper extremity ischemia 385, 386
aortic dissection 355, 362, 363
cerebral aneurysms 302
critical leg ischemia 317–18, 326–7, 327,
342–3
interatrial septum (IAS) 255, 256, 257,
260–2
mesenteric ischemia 443, 449–50
percutaneous coronary see percutaneous
coronary intervention
renal artery 370, 371–4
right ventricular outflow tract 269–70
TIPS procedure 394, 394
stents
 coronary artery see coronary artery stents
interatrial septum 301
mesenteric ischemia 451–2, 452
saphenous vein graft PCI 119
unprotected left main coronary artery
(ULMCA) 183–4
see also bare metal stents; covered stents;
drug-eluting stents
stent thrombosis, coronary artery 487–90,
491, 492
STENTYS Self-Apposing stent 491–2
STOPAMI trials 138, 140
streptokinase 107, 159, 289
stroke
acute see acute stroke
rehabilitation 284–5
steps in management 281–5, 282
stroke centers/units 280–1, 283, 284
stomal cell-derived factor-1 (SDF-1),
critical limb ischemia 523
structural heart disease, acute 198–200
ST-segment elevation myocardial infarction
(STEMI) 3, 91–7
aqueous oxygen treatment 502–7
cardiogenic shock 153–4, 155–65, 156
diagnosis 91
drug-eluting balloons 146–50, 148
endovascular hypothermia 510–12
eximer laser revascularization 126–34,
127, 129
ﬁbrolysis see thrombolytic therapy,
STEMI
interventional centers 95
late presentation 137–43, 139
mechanical reperfusion 140–2
medical therapy 142–3
pathophysiology 138–40
 treatment flowchart 141
left main disease 180–1, 181, 181
long-term management 171–7
pathophysiology 4–5
prehospital diagnosis and transfer 95
primary PCI see under percutaneous
coronary intervention
radial artery access 112, 114, 114
treatment strategies 5, 91–7
management system 94–5
symptom duration and 92–3, 93, 94
subarachnoid hemorrhage (SAH) 307
subclavian approach, transcatheter aortic
valve implantation 212, 212–13
subclavian steal syndrome 379, 381
subintimal recanalization, critical limb
ischemia 324–5
superﬁcial femoral artery (SFA)
interventions, critical limb
ischemia 321–8
superior mesenteric artery (SMA)
acute occlusion 443, 451
chronic occlusion 446–8, 447
diabetic interventions 443, 448–50,
449–50
imaging of stented 453, 453
superior vena cava (SVC) ﬁlters 469
insertion technique 470
supersaturated oxygen (SSO2) therapy,
STEMI 503, 503–7
clinical results 503–5, 504–6, 505
subvenous atrial arrhythmias, emergent
ablative therapy 194
Surpass device 303, 307
SWISS II trial 141–2
Symbiot III trial 119
tachycardia-induced cardiomyopathy 193
TACT study 524, 530
Takayasu disease 446
TALISMAN study 521
TAMARIS trial 521
TandemHeart device 163, 163, 164–5, 183,
195
TAO study 80, 81–2
TAPAS study 100, 141, 487
TASC (Trans Atlantic Inter Society
Consensus) classiﬁcation 331, 332
technetium-99m-tagged red blood cell scan,
critical GI bleeding 459
telemecidine, STEMI 95
tenecteplase (TNK) 290
acute upper extremity ischemia 386
STEMI 107, 108
tetralogy of Fallot 270, 272
TherOx AO system 503, 503
thienopyridines 87, 485
see also clopidogrel; prasugrel
thin-cap ﬁbroatheroma (TCFA) 19
intravascular ultrasound 21, 21
optical coherence tomography 22, 22–3
thoracic endovascular repair
(TEVAR) 354–5
thoracic outlet syndrome 379
thrombectomy
acute coronary syndromes 95, 96,
99–103, 128–9, 487
eximer laser 126–34
late-presenting STEMI 141
manual aspiration 99, 100, 101, 102–3
mechanical aspiration devices 99,
100–1, 128
meta-analyses of studies 488–9
acute stroke 292–4, 293, 294
acute upper extremity ischemia 385
power 128
pulmonary embolism 204, 204–5, 535
rheolytic see rheolytic thrombectomy
thrombin inhibitors, direct see direct
thrombin inhibitors
thrombin time 71
thromboangiitis obliterans 380
thrombolytic therapy (ﬁbrinolytic therapy)
acute mesenteric ischemia 443, 445
acute pulmonary embolism
catheter directed 204, 535
contraindications 202
systemic 201, 202, 535
ultrasound-accelerated 205, 205,
536–9
acute stroke 289–91
contraindications 288
echocamton microphers and
297
hemorrhagic complications 295,
297–8, 298
intra-arterial 295–7
intravenous 287, 290–1
acute upper extremity ischemia 383–4,
386
agents available 106, 289–90
mechanism of action 106, 107
STEMI 105–8
alternatives to 108
beneﬁts 105, 106
with cardiogenic shock 159
facilitating primary PCI 108
follow-up treatment 107
indications 106–7
late presentation 137–8, 140
organization 95
prehospital 92
preventing heart rupture 238
risks 107
symptom duration and 92–3, 93, 94
vs primary PCI 91–2, 108
ultrasound-accelerated see ultrasound-
accelerated thrombolysis
thrombomodulin 9
thrombosis
acute mesenteric ischemia 442, 443
acute upper extremity 379
around inferior vena cava ﬁlters
471, 471
ventricular septal defects (VSD)
postinfarction 200, 238–42
diagnosis 238
percutaneous closure 239–42, 240, 241, 247–8
surgical closure 239
treatment 238–42
transcatheter closure 199–200, 244–51
indications 244–5, 245
outcomes 247–50, 250
percutaneous technique 245–7, 246
perventricular technique 247, 248, 249
ventricular tachycardia (VT)
emergent ablative therapy 193, 194–6
reperfusion 187, 189, 190
surgical cardiac denervation 196
transcoronary pacing during PCI 547
verapamil
reperfusion arrhythmias 189–90, 190
saphenous vein graft PCI 122
VerifyNow platelet reactivity testing system 44–5
Virtual Histology (VH-IVUS), coronary plaque 20–1, 21, 22–3
visceral arteriovenous malformations (AVMs) 428
vitamin K, administration 72
vitamin K antagonists (VKAs) 63
management of bleeding 72–3
see also warfarin
vitamin supplements 175
von Willebrand factor 9
deficiency, Heyde’s syndrome 211
VSD see ventricular septal defects
vulnerable (coronary artery) plaque 19–24
imaging methods 19–23
interventional treatment 24
warfarin 27, 63
acute coronary syndromes 173–4
management of bleeding 72–3
monitoring 71
WEB II device 310
weight management 172
Wilkins–Abascal scoring system 232
Wingspan stent system, acute stroke 294–5
Wolff–Parkinson–White (WPW) syndrome, emergent ablative therapy 194
wound healing, by extracorporeal shock wave therapy 549–57
X*Calibur AOD 303, 307
ximelagatan 27, 32, 33, 35
X-PLOER trial 80
X-Sizer catheter 487
Z-5 septostomy catheter 257, 258, 259
zotarolimus-eluting balloons 147